(lp0
S"Why Puma Biotechnology Inc. Got Hammered Today Motley Fool - Mar 2, 2017 The potential to establish a new standard of care where patients take Herceptin and Perjeta for a year could be problematic for Puma Biotechnology because its drug candidate, neratinib, was tested after just Herceptin use, the current standard of care.Puma Biotech shares plummet 26% after Roche reports positive results for late ... - MarketWatchHere's What Analysts Are Asking Puma Biotech Following Roche's Positive ... - Benzinga"
p1
aS'Lookout for Price Target? EP Energy Corporation , Puma Biotechnology, Inc ... StockNewsJournal - 18 hours ago Puma Biotechnology, Inc. , at its latest closing price of $40.25, it has a price-to-book ratio of 7.80, compared to an industry average at 10.15.Puma Biotechnology Inc  Plunges 9.45% on March 21 - Equities.comBullish Target Of Puma Biotechnology Inc  At $89 - Stock Observer'
p2
aS"Thursday's Biotech Insights: Aurinia Pharmaceuticals Inc , Puma ... Smarter Analyst - Mar 2, 2017 Puma Biotechnology Inc  shares lost one-quarter of their value today, after competitor Roche announced positive top-line results from the highly anticipated APHINITY trial, which explores usefulness of Perjeta in adjuvant breast cancer ...Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA ... - Benzinga"
p3
aS'Analytical Guide for Puma Biotechnology, Inc. , Liberty Property Trust ... The USA Commerce - 19 hours ago Presently Puma Biotechnology, Inc.  stock have an ABR of 1.67. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.'
p4
aS'Why Puma Biotechnology Inc. Sold Lower Today Motley Fool - Oct 19, 2016 Puma Biotechnology is looking to raise $150 million selling shares, which will dilute current shareholders. Another $22.5 million of shares could also be sold within 30 days if the underwriters want the extra shares.Puma Biotechnology Inc  Swamped by New Shares - Scibility MediaPuma Biotechnology Announces Proposed Public Offering of Common Stock - Business Wire '
p5
aS"Why Puma Biotechnology Inc Roared Higher Today Motley Fool - Sep 20, 2016 Puma Biotechnology  was up as much as much as 15% today after announcing that the Food and Drug Administration accepted the company's marketing application for its breast cancer drug neratinib, although it's given up some of that gain&nbsp;...JP Morgan Comments on Puma Biotechnology Inc  Following NDA Acceptance - Smarter AnalystPuma Biotechnology Announces US FDA Acceptance of New Drug Application for ... - Business Wire "
p6
aS'Puma Biotechnology Inc  Moves Higher on Volume Spike for March 17 Equities.com - Mar 17, 2017 Puma Biotechnology Inc  traded on unusually high volume on Mar. 17, as the stock gained 0.91% to close at $44.15. On the day, Puma Biotechnology Inc saw 2.2 million shares trade hands on 7,459 trades. Considering that the stock averages only a&nbsp;...Brokerages Set Puma Biotechnology Inc  PT at $70.50 - Chaffey Breeze'
p7
aS'PUMA BIOTECHNOLOGY, INC.  Files An 8-K Other Events Market Exclusive - Mar 1, 2017 Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer.Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results - Yahoo Finance'
p8
aS'Market Check: Narrowing in on Shares of Puma Biotechnology, Inc.  Baldwin Journal - 16 hours ago Puma Biotechnology, Inc.  currently has a 6 month price index of 0.61003. The six month price index is simply measured by dividing the current share price by the share price six months ago.'
p9
aS"Trading Spotlight: Zooming in on Shares of Puma Biotechnology Inc  The Standard - 13 hours ago Puma Biotechnology Inc 's current 14-day Willams %R value has been spotted at -37.05. Values can span from 0 to -100."
p10
a.